Merck Shares Outstanding 2010-2022 | MRK

Merck shares outstanding history from 2010 to 2022. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Merck shares outstanding for the quarter ending June 30, 2022 were 2.540B, a 0% increase year-over-year.
  • Merck 2021 shares outstanding were 2.538B, a 0.12% decline from 2020.
  • Merck 2020 shares outstanding were 2.541B, a 1.51% decline from 2019.
  • Merck 2019 shares outstanding were 2.58B, a 3.7% decline from 2018.
Merck Annual Shares Outstanding
(Millions of Shares)
2021 2,538
2020 2,541
2019 2,580
2018 2,679
2017 2,748
2016 2,787
2015 2,841
2014 2,928
2013 2,996
2012 3,076
2011 3,094
2010 3,120
2009 2,273
Merck Quarterly Shares Outstanding
(Millions of Shares)
2022-06-30 2,540
2022-03-31 2,537
2021-12-31 2,538
2021-09-30 2,536
2021-06-30 2,540
2021-03-31 2,541
2020-12-31 2,541
2020-09-30 2,538
2020-06-30 2,536
2020-03-31 2,547
2019-12-31 2,580
2019-09-30 2,572
2019-06-30 2,588
2019-03-31 2,603
2018-12-31 2,679
2018-09-30 2,678
2018-06-30 2,696
2018-03-31 2,710
2017-12-31 2,748
2017-09-30 2,727
2017-06-30 2,752
2017-03-31 2,766
2016-12-31 2,787
2016-09-30 2,786
2016-06-30 2,789
2016-03-31 2,795
2015-12-31 2,841
2015-09-30 2,836
2015-06-30 2,850
2015-03-31 2,865
2014-12-31 2,928
2014-09-30 2,911
2014-06-30 2,949
2014-03-31 2,971
2013-12-31 2,996
2013-09-30 2,960
2013-06-30 3,010
2013-03-31 3,053
2012-12-31 3,076
2012-09-30 3,079
2012-06-30 3,072
2012-03-31 3,074
2011-12-31 3,094
2011-09-30 3,091
2011-06-30 3,110
2011-03-31 3,104
2010-12-31 3,120
2010-09-30 3,102
2010-06-30 3,125
2010-03-31 3,141
2009-12-31 2,273
2009-09-30 2,114
2009-06-30 2,110
2009-03-31 2,109
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $217.457B $48.704B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $433.657B 16.51
Eli Lilly (LLY) United States $295.599B 37.48
AbbVie (ABBV) United States $250.575B 10.65
Pfizer (PFE) United States $247.449B 7.25
Novo Nordisk (NVO) Denmark $217.019B 28.63
Novartis AG (NVS) Switzerland $165.171B 12.18